Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Other financing activities (2020 - 2021)

Barinthus Biotherapeutics (BRNS) has disclosed Other financing activities for 2 consecutive years, with $1.4 million as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Other financing activities changed N/A year-over-year to $1.4 million, compared with a TTM value of $2.2 million through Dec 2021, changed N/A, and an annual FY2021 reading of $2.2 million, up 3698.25% over the prior year.
  • Other financing activities was $1.4 million for Q3 2021 at Barinthus Biotherapeutics, up from $756000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $1.4 million in Q3 2021 and bottomed at $22000.0 in Q1 2021.